ArticleThe Lancet regional health. Europe2025
Longitudinal data on advanced cutaneous squamous cell carcinoma from the Dutch Keratinocyte Cancer Collaborative (DKCC): a nationwide real-world database study.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While Cutaneous Squamous Cell Carcinoma (CSCC) is one of the most common cancers, epidemiological data is scarce. Therefore, the aim of this study was to collect high quality epidemiological data, which is needed to identify differences in outcomes and improve patient care. To achieve this aim, we designed the Dutch Keratinocyte Cancer Collaborative (DKCC), which is a nationwide database, including longitudinal data on locally advanced, recurrent, and metastatic CSCC (advanced CSCC). Methods: Advanced CSCCs were identified from the Dutch nationwide Pathology Databank (Palga) using a validated algorithm. Manual registration of a selection of 500 patients with advanced CSCC per year (all metastatic, all recurrences and a random selection of locally advanced CSCCs) was performed by the Netherlands Cancer Registry to obtain data on tumour characteristics, diagnostics, disease progression and treatment. Data was linked to the Netherland Organ Transplant Registry to obtain information about immunosuppressed patients and to the municipal records for vital status. Findings: We estimated that 8.0% (1846/23,065 CSCC, 95% confidence interval: 7.4-8.6) of all diagnosed CSCC in 2021 were locally advanced CSCC. In 2021-2022, 920 patients with advanced CSCC were registered in the DKCC. A quarter of metastatic patients had recurrent CSCC before developing metastasis (i.e., 13/51 patients with skin metastasis, 63/296 patients with regional lymph node metastasis, 20/72 patients with distant metastasis). The median time to recurrence or metastasis after an American Joint Committee on Cancer (AJCC) T3/T4 primary CSCC was 11 months (Interquartile range [IQR] 6-19) and 9 months (IQR 6-17), respectively. In 6% (4/67, skin metastasis only) to 20% (17/83, distant metastasis) of episodes with metastasis, no treatment was provided. Interpretation: The DKCC is the first nationwide longitudinal data source on advanced CSCC. Its methodology can serve as an example for designing efficient registries for advanced CSCC in other countries or even for other rare cancer outcomes. The high number of locally advanced CSCC puts a large burden on the health care system, as these patients need more extensive work-up and treatment. Data from the DKCC provides essential information to improve clinical guidelines for optimal CSCC patient care. Funding: Funded by Sanofi Genzyme/Regeneron.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.